SUMMARY S is a large-scale, prospective, international, multicentre, double-blind, double-dummy, randomized, parallel-group trial. Patients with exacerbation of osteoarthritis were treated with the recommended dose of meloxicam (7.5 mg) or piroxicam (20 mg) once daily for 28 days; 4320 patients were administered meloxicam and 4336 piroxicam. The incidence of adverse events was significantly lower in the meloxicam group (22.5%) compared with the piroxicam group (27.9%; P < 0.001), mainly due to the significantly lower incidence of gastrointestinal (GI ) adverse events in the meloxicam than in the piroxicam group (10.3% vs 15.4%; P < 0.001), while the efficacy of both drugs was equivalent. Individual GI events occurred significantly less often with meloxicam than piroxicam: dyspepsia (3.4% vs 5.8%; P < 0.001), nausea/vomiting (2.5% vs 3.4%; P < 0.05) and abdominal pain (2.1% vs 3.6%; P < 0.001). There were 16 patients with perforations, ulcerations or bleeding (PUBs) of the upper GI tract in the piroxicam group compared with seven in the meloxicam group (relative risk piroxicam:meloxicam = 1.4). Four PUBs were complicated (perforations or bleedings); none of these occurred in the meloxicam group (relative risk piroxicam:meloxicam = 1.9). The outcome of S is consistent with that of the large-scale clinical trial of similar design and size which compared 7.5 mg meloxicam with 100 mg diclofenac in patients with osteoarthritis, and with a previous global analysis of the safety of meloxicam. It adds further data to the proposed relationship between selective inhibition of cyclooxygenase-2 and improved GI tolerability of non-steroidal anti-inflammatory drugs.
T investigate further the hypothesis of improved ibuprofen have been obtained so far in patients with acute flares of osteoarthritis (OA). tolerability with selective cyclooxygenase (COX )-2 inhibitors, the present study was performed in conjuncSignificant advantages with regard to efficacy were observed for meloxicam 15 mg in one study compared tion with a separate study, with a similar design and size, comparing meloxicam 7.5 mg to diclofenac slow to piroxicam 20 mg [5] . In short-and long-term treatment, meloxicam 15 mg showed, although not statisticrelease (SR) 100 mg [1] . These two large-scale comparisons intended to compare at recommended ally significantly different, larger improvements in pain scores than piroxicam 20 mg [6, 7] . equi-effective doses the overall safety of meloxicam to established non-steroidal anti-inflammatory drugs On the basis of these studies, international registration for meloxicam was granted with meloxicam 7.5 mg (NSAIDs), with diclofenac being among the least toxic NSAIDs and piroxicam [2] having a high ranking in being the recommended dose for the symptomatic treatment of acute flares of OA. Hence, meloxicam comparison to other NSAIDs [3] .
Meloxicam 7.5 mg and 15 mg was investigated in a 7.5 mg was selected for comparison to piroxicam 20 mg, which was thought to be of comparable efficacy number of double-blind randomized clinical trials in comparison to several NSAIDs, including piroxicam, based on the results of previous trials. For ibuprofen, so far no equi-effective dose in the diclofenac and naproxen, leading to international registration. Overall, meloxicam has been shown to have a treatment of acute flares of OA compared to meloxicam has been established. favourable gastrointestinal (GI ) tolerability profile compared with these standard NSAIDs [4] . No comIn particular, the aim of this large-scale trial was to identify possible differences between meloxicam and parative efficacy and safety data of meloxicam to the standard NSAID, piroxicam, in overall safety and particularly in terms of GI tolerability, and to provide to COX-1.
PATIENTS AND METHODS
demographic characteristics and concomitant diseases, and were considered to be representative of the general This was a prospective, large-scale, double-blind, population of patients with OA ( Table I ) . double-dummy, randomized trial conducted internationally in 12 countries. The trial protocol was Tolerability assessments developed and the trial was monitored by a steering Patients on meloxicam 7.5 mg reported fewer adverse committee consisting of the authors with representevents (22.5%) than those on piroxicam 20 mg (27.9%; atives from Boehringer Ingelheim. The trial was P < 0.001). The difference in adverse events between approved by the appropriate ethics committees and the two treatments was attributable to those affecting was conducted in accordance with the Declaration of the GI tract. GI adverse events were found to occur Helsinki and good clinical practice. Most patients were significantly less commonly with meloxicam (10.3%) recruited from general practice. All patients gave writthan piroxicam (15.4%; P < 0.001), as shown in ten informed consent. Table II . Dyspepsia, nausea and vomiting, abdominal The design, clinical protocol, assessments of tolerpain and diarrhoea were the most commonly reported ability, safety and efficacy, as well as statistical individual events in the GI category and, with the methods, were identical to those of another large-scale exception of diarrhoea, occurred significantly less often comparison of meloxicam 7.5 mg with diclofenac with meloxicam (P < 0.05 at least; Fig. 1 terms of withdrawals due to GI adverse events were evaluated on an intent-to-treat basis for safety ( Table II ) , the difference in favour of meloxicam was and efficacy ( Table I ) . Of these, 4320 were treated with significant (3.8% vs 5.3%; P < 0.01; odds ratio 0.71, meloxicam 7.5 mg and 4336 with piroxicam 20 mg. 95% CI 0.58-0.87). In subpopulations of elderly and The median time on study medication was calculated younger males and elderly and younger females, the to be 28 days. In both treatment groups, 79% of frequency of GI adverse events was always significantly patients were pre-treated with NSAIDs. The trial was higher (except in elderly males) in the piroxicam-than completed by 89% in the meloxicam group and 88% in the meloxicam-treated patients. Within treatment in the piroxicam group. Approximately 5% of all groups, the incidences of GI adverse events in males patients were treated with drugs for peptic diseases were comparable for those in the elderly (>65 yr) and (antacids, proton pump inhibitors, H 2 -blockers) before, younger (∏65 yr) age groups (piroxicam 13.91% vs and continued during, the trial (4.6% in the meloxicam 13.03%; meloxicam 9.95% vs 10.04%). Fewer elderly group, 5.6% in the piroxicam group). Overall, the two than younger females treated with meloxicam reported treatment groups were comparable with respect to GI adverse events (9.02% vs 11.42%). Although there was a small difference between elderly and younger ulcer, one perforated GI ulcer, one GI and duodenal ulcer).
P < 0.001) which was mainly due to the significantly †Patient suffered from concomitant duodenal and gastric ulcer, and haematemesis.
lower incidence of GI adverse events with meloxicam. ‡One patient had both gastric and duodenal ulcer.
The incidences of adverse events affecting other body §One patient had concomitant duodenal ulcer and melaena.
systems were low (<5%), differences between treatment groups for all body systems were <1%. Out of a total of 1671 adverse events in the meloxpatients in the piroxicam group were hospitalized for GI adverse events. The mean duration of hospital stay icam group, 1471 were classified as mild or moderate and 194 as severe in intensity (six unclassified). The for GI adverse events was lower in the meloxicam group than the piroxicam group (9 days vs 17 days, corresponding figures for piroxicam were 2121 adverse events in total; 1912 mild or moderate, 202 severe and respectively), as was the total duration of hospital stay for GI adverse events (56 days vs 121 days). seven unclassified. Overall, 54 and 59.5% of all adverse events were considered to be related to treatment with
The median laboratory values of the blood chemistry, haematology and differential blood cell count did meloxicam and piroxicam, respectively; furthermore, there was a lower frequency of withdrawals due to all not indicate any relevant changes between baseline and the end of the treatment period. The values showed adverse events ( Table II ) with meloxicam than piroxicam, that fell short of statistical significance (6.1% vs significantly fewer increases of serum creatinine (2.4% vs 3.4%; P < 0.01) and urea (8.8% vs 17.7%; P < 0.01) 7.2%; P = 0.06). There was no significant difference between treatments in relation to serious adverse from the normal into the range above the upper limit of normal in favour of meloxicam compared with events (26 patients on meloxicam, 30 on piroxicam; P = 0.69). Serious adverse events considered related piroxicam. There were no significant differences in relevant changes of haemoglobin and haematocrit to treatment occurred rarely, and with similar frequency, in the meloxicam and piroxicam groups (7 vs between the two treatment groups. 11). In the evaluation of global tolerability, the treatment groups were comparable (combined 'good'/'satis-
Efficacy assessments
The reduction in pain on active movement, assessed factory' categories) as judged by physicians or patients (both assessments: meloxicam 90% vs piroxicam 88%).
by 100 mm visual analogue scale ( VAS ), was comparable with meloxicam and piroxicam and not signifiSix patients in the meloxicam group and seven ( Table IV ) . The change in patients' arthritic condition improved from a mean value of 3.2 at baseline to 2.0 at the end of treatment with both drugs. The final judgement of the patients' arthritic status was comparable with meloxicam and piroxicam (66% vs 70% of patients improved, respectively). In addition, at the end of treatment, the percentage of patients rating global efficacy with meloxicam and piroxicam as 'good' or 'satisfactory' was 70 and 73%, respectively; the corresponding proportions for physician-rated global efficacy were 71 and 75%, respectively.
DISCUSSION
The large-scale S (Safety and Efficacy Largescale Evaluation of COX-inhibiting Therapies) trial demonstrated that there was a significant advantage for meloxicam compared with piroxicam with regard to the frequency of GI adverse events in a population less likely to be withdrawn due to GI adverse events. The overall adverse event rate was significantly lower in meloxicam-than piroxicam-treated patients, mainly cantly different ( Fig. 2a) . The mean reduction from due to the lower GI adverse event rate with meloxicam. baseline to the end of the trial was −31 mm (−45%)
Meloxicam was associated with fewer ulcerations of with meloxicam and −33 mm (−47%) with piroxicam.
the upper GI tract, including fewer complications The mean treatment difference at the end of the trial (perforation or bleeding) than piroxicam, but, as was 1.97 mm (95% CI 1.01-2.94 mm) which is within expected in a trial of 4 weeks duration [9] , the incithe predefined equivalence region of 17 mm [8] . A dences were too low to show a statistically significant similar pattern was observed with pain at rest, with no difference (P < 0.1). significant difference between treatments; the mean In respect of GI tolerability, our findings are conchange from baseline to the end of treatment was sistent with those of another large-scale trial, the −25 mm (−48%) with meloxicam and −27 mm Meloxicam Large-scale International Study Safety (−51%) with piroxicam (Fig. 2b) . The mean treatment Assessment (M). Like S, M was a difference at the end of the trial was 1.54 mm (95% CI prospective, randomized, double-blind trial; 4635 OA 0.54-2.54 mm) which is again within the predefined patients received treatment with meloxicam 7.5 mg equivalence region of 10.5 mm [8] .
once daily and 4688 received diclofenac 100 mg SR for Seventy-five meloxicam-treated patients (1.7%) and 28 days. In common with S, there were fewer GI 68 piroxicam-treated patients (1.6%) withdrew premaadverse events reported for meloxicam compared with turely due to lack of efficacy. the comparator group (13% vs 19%; P < 0.001). Based on the predefined equivalence boundaries [8] , Moreover, individual events (dyspepsia, nausea and meloxicam and piroxicam were also shown to be vomiting, abdominal pain and diarrhoea) occurred equivalent with regard to all other efficacy assessments, with no significant differences between treatments significantly less often with meloxicam than diclofenac *Based on four-point scale (1 = good; 2 = satisfactory; 3 = not satisfactory; 4 = bad). †Based on three-point scale (1 = improved; 2 = unchanged; 3 = deteriorated ).
(P < 0.05 at least). Efficacy was comparable for both found to be lower with meloxicam than piroxicam in every group. NSAIDs.
Furthermore, the results of both S and M The results of S, together with the results of M and the global analysis of meloxicam studies, confirm a global analysis of safety data from meloxicam clinical trials [10] . In this analysis, meloxicam are supportive of the view that meloxicam has a GI tolerability profile superior to that of piroxicam and 7.5 mg and 15 mg (n = 4175) were compared with piroxicam 20 mg (n = 906), diclofenac 100 mg SR other standard NSAIDs. The importance of the superiority of the tolerability profile and the related improve-(n = 324) and naproxen 750-1000 mg (n = 243). Both doses of meloxicam were significantly better tolerated ment can be approximated by calculating the relative differences of adverse event incidences, which are of than all comparator NSAIDs in terms of all GI adverse events, and, in most cases, significantly better tolerated the order of 19-30%. For adverse events in general, this figure is 19% (22.5 vs 27.9), for GI adverse events than comparator drugs with respect to severe GI events, discontinuations due to GI events, individual it is 33% (10.3 vs 15.4), and for GI adverse events in patients with a previous history of PUB it is 19% (24.6 GI events (dyspepsia, abdominal pain), and unspecified upper GI adverse events. After 30 days of treatment, vs 30.2). For increases in creatinine and urea above the upper limit of normal, the respective figures are 29 13% of patients on meloxicam 7.5 mg reported GI adverse events compared with 19% on diclofenac, and 50%. These approximations are somewhat conservative as they do not take the placebo incidences into 17.6% on piroxicam and 11% on placebo [4] .
The number of patients affected by PUB-related account. GI adverse events have been observed to occur under 3 weeks of placebo treatment with an complications during S was lower in the meloxicam group than in the piroxicam group (7 vs 16) and incidence of around 11% [4] . The reason for the difference in tolerability between the number of complications (perforations or bleeding) was also lower (one questionable ulcer complication meloxicam and piroxicam may lie in differences in their relative inhibition of COX-1 and COX-2 [11]. on meloxicam vs four definite ulcer complications on piroxicam), although the difference did not achieve
Meloxicam is a member of a new class of NSAIDs that have been shown to be more selective for COX-2 statistical significance (P < 0.1). These figures for meloxicam support those from M, where five than COX-1 [11, 12] , and this property may explain its improved GI tolerability. Piroxicam, on the other patients reported PUBs on meloxicam, all of which were uncomplicated, i.e. no perforations or bleeding, hand, strongly inhibits both COX-1 and COX-2 at therapeutic concentrations, and shows some preference compared with seven reports on diclofenac, four of which were complicated. The low incidences of PUBs for COX-1 in vitro [13, 14] , possibly explaining the associated greater risk of serious GI side-toxicity, in both these studies may be accounted for by the short (4 week) duration of treatment. In the global compared with some other NSAIDs, seen in epidemiological studies [3] . The results of S lend further analysis of safety data already reported from meloxicam clinical trials, the incidence of PUBs was sigsupport to this theory, since the major difference in tolerability between the two drugs lay in those effects nificantly lower with meloxicam 7.5 mg than with piroxicam 20 mg (0.1% vs 1.2%; P < 0.05) over a thought typically to be mediated by COX-1. A longer study duration might have been expected to show even period of 6 months [10] . Consistent with these results is the observation that treatment with meloxicam was greater differences between the two drugs with respect to serious GI toxicity. associated with a lower average duration of hospital stay, and a lower total duration of hospital stay, for
NSAIDs that selectively inhibit COX-2 relative to COX-1 may prove to be an important step forward in GI adverse events. This is the first trial comparing piroxicam 20 mg, a developing better tolerated treatment for OA, and thus reducing the morbidity and mortality associated with dose commonly used in general practice for OA, with meloxicam 7.5 mg. The efficacy of meloxicam and standard NSAIDs. piroxicam was equivalent, as shown in a range of CONCLUSIONS standard efficacy parameters. This finding confirms the results from previous studies [5] [6] [7] which were the In S, one of the largest prospective, doubleblind trials to compare the tolerability of two NSAIDs, basis for the dose recommendation of meloxicam in international registrations. These results of S are meloxicam induced significantly fewer GI adverse events than an equi-effective dose of piroxicam. consistent with those of the M trial in which the efficacy of meloxicam 7.5 mg was shown to be equivaMeloxicam treatment was also associated with fewer perforated or bleeding ulcers than treatment with lent to diclofenac 100 mg SR. NSAIDs should be used cautiously in patients known to be at risk of upper GI piroxicam. These findings were consistent with the results of the M study and a pooled analysis of tract bleeding, including the elderly or those with a history of peptic ulcer. In S, the number of double-blind clinical trials, which have demonstrated that meloxicam has an improved GI tolerability profile elderly patients (>65 yr old) and the number of patients with a peptic ulcer history was similar in compared with equi-effective doses of the standard NSAIDs piroxicam, diclofenac and naproxen. both treatment groups. When subgroups of younger (∏65 yr) and elderly (>65 yr) male and female patients
The COX concept predicts that COX-2 inhibition underlies the efficacy of NSAIDs, whilst their toxicity were analysed, the incidence of GI adverse events was
